<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYCLOPENTOLATE HYDROCHLORIDE - cyclopentolate hydrochloride solution/ drops </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Cyclopentolate Hydrochloride <br>Ophthalmic Solution USP, 1% <br>(Sterile)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c09c1f9-3acd-4f82-a8f1-f42ed2306501"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_ec11b513-a470-403d-8040-07dac7b307a3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% is an anticholinergic prepared as a sterile, borate buffered, solution for topical ocular use. The active ingredient is represented by the following structural formula:</p>
<div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0504a84a-0ba4-483b-9682-9bf3818410ee&amp;name=8c18b647-b48f-4639-8092-90632bb491d3-01.jpg"></div>
<p>C<span class="Sub">17</span>H<span class="Sub">25</span>NO<span class="Sub">3</span> • HCl<br>Mol. Wt. 327.85</p>
<p>Chemical name: 2-(Dimethylamino) ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride.</p>
<p><span class="Bold">Each mL Contains:</span></p>
<p>ACTIVE: Cyclopentolate Hydrochloride, 10 mg (1%)</p>
<p>INACTIVES: Boric Acid, Potassium Chloride, Edetate Disodium, Purified Water. Sodium Carbonate and/or Hydrochloric Acid may be added to adjust pH (3.0-5.5).</p>
<p>PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9a37e97e-d6e5-40ed-a29d-952ae444d871"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (<span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>) and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of accommodation (<span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>). It acts rapidly, but has a shorter duration than atropine. Maximal <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> in some individuals may require several days.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_1f7a78ef-7f37-4fab-802f-9ca92bdcdf71"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Cyclopentolate Hydrochloride Ophthalmic Solution is used to produce <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> and <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> in diagnostic procedures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ad2e7918-087b-4e9a-a4bb-cb6a182761cc"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Should not be used when narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or anatomical narrow angles are present, or where there is <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this preparation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_a791b50b-6770-4e25-b4d7-e7ead22c72e0"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">For Topical Use Only - Not For Injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger cyclopentolate hydrochloride solution. Premature and small infants are especially prone to CNS and cardiopulmonary side effects from systemic absorption of cyclopentolate. To minimize absorption, use only 1 drop of a 0.5% solution per eye followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9b6eb201-eaa0-489a-82b7-904e494b95cd"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_3a10b63d-7250-4ca8-a26e-8d3a487ce05b"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">To avoid inducing <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>, an estimation of the depth of the angle of the anterior chamber should be made. The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to avoid excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down’s syndrome or mongolism, and in those predisposed to angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_901a6956-2696-49b2-9184-9beb263b4de4"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Do not touch dropper tip to any surface as this may contaminate the solution. A transient <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child’s mouth and to wash their own hands and the child’s hands following administration.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_d7529092-ef6d-4722-bfee-c65bad57c076"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Cyclopentolate may interfere with the antiglaucoma action of carbachol or pilocarpine; also, concurrent use of these medications may antagonize the anti-<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and miotic actions of ophthalmic <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4346559f-51d0-4035-b889-afe3dd183561"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Studies in animals or humans have not been conducted to evaluate the potential of these effects.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_e89d423d-4f45-46d9-b971-32f2e1d8cb36"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy Category C:</h2>
<p class="First">Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_970b1962-1570-4de9-98d9-99aafa8cb279"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_08923391-f993-4504-835a-9d9f0846b7ff"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Increased susceptibility to cyclopentolate has been reported in pediatric patients with <span class="product-label-link" type="condition" conceptid="4300746" conceptname="Spastic paralysis">spastic paralysis</span> or <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. Therefore, cyclopentolate should be used with great caution in these patients. Feeding intolerance may follow ophthalmic use of this product in neonates. It is recommended that feeding be withheld for four (4) hours after examination. Do not use concentrations higher than 0.5% in small infants (see <span class="Bold"><a href="#i4i_warnings_id_a791b50b-6770-4e25-b4d7-e7ead22c72e0">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_306834b7-be85-4e25-bfd3-7b767aa58785"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">In the elderly and others where <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> may be encountered, mydriatics and cycloplegics should be used cautiously.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_5006664b-4ace-4276-b69c-adb07942a220"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First"><span class="Bold">Ocular: </span><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span>, burning, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, irritation, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">punctate keratitis</span>, synechiae.</p>
<p><span class="Bold">Systemic: </span>Use of cyclopentolate has been associated with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> and behavioral disturbances, usually in pediatric patients, especially with a 2% concentration. These disturbances include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, incoherent speech, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> in infants, unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, medullary <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b168ae52-d068-410f-8bcf-5c241b7e72b8"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Excessive dosage may produce exaggerated symptoms as noted in <span class="Bold"><a href="#i4i_adverse_effects_id_5006664b-4ace-4276-b69c-adb07942a220">ADVERSE REACTIONS</a></span>. When administration of the drug product is discontinued, the patient usually recovers spontaneously. In case of severe manifestations of toxicity the antidote of choice is physostigmine salicylate.</p>
<p><span class="Bold">Pediatric Dose: </span>As an antidote, slowly inject intravenously 0.5 mg physostigmine salicylate. If toxic symptoms persist and no cholinergic symptoms are produced repeat at five minute intervals to a maximum cumulative dose of 2 mg.</p>
<p><span class="Bold">Adolescent and Adult: </span>As an antidote, slowly inject 2 mg physostigmine salicylate intravenously. A second dose of 1 to 2 mg may be given after 20 minutes if no reversal of toxic manifestations has occurred. <span class="Sup">1, 2, 3</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5d7209fd-ccfc-4614-9ab3-91902a309e7e"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First"><span class="Bold">Adults: </span>One or two drops of 0.5%, 1% or 2% solution in the eye, which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours.</p>
<p><span class="Bold">Pediatric Patients: </span>One or two drops of 0.5%, 1% or 2% solution in the eye, which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary.</p>
<p><span class="Bold">Small Infants: </span>A single instillation of one drop of 0.5% solution in the eye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation.</p>
<p>Individuals with heavily pigmented irises may require higher strengths.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5921f8f2-e2ac-483a-b3fb-a325c76d418f"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% is available in multidose plastic squeeze bottles with a controlled drop tip and red cap in the following sizes:</p>
<p><br></p>
<p>15 mL bottle - Prod. No. 04911     <span class="Bold">NDC 54868-4697-1</span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_08ff479a-1a9b-40bd-acc3-c42cd1ca6c47"></a><a name="section-11.1"></a><p></p>
<h2>Storage:</h2>
<p class="First">Store between 15°-30°C (59°-86°F).</p>
<p><span class="Bold">FOR OPHTHALMIC USE ONLY</span></p>
<p><span class="Underline"><span class="Bold">DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.</span></span></p>
<p>KEEP OUT OF REACH OF CHILDREN.<br><br></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_0e773f47-d7e7-43fe-857e-1ffedfb95c63"></a><a name="section-12"></a><p></p>
<p class="First">1. Rumack, B.H.: Anticholinergic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>: Treatment with Physostigmine. Pediatrics 52(6): 449-51, 1973.</p>
<p>2. Duvoisin, R.C. and Katz, R.: Reversal of Central Anticholinergic Syndromes in Man by Physostigmine, J. Am. Med. Assn. 206(9): 1963-65,1968.</p>
<p>3. Grant, W.M.: Toxicology of the Eye. Second Edition, Volume 1. Springfield, Illinois, Charles C. Thomas: 1974.<br><br><br></p>
<p>Revised November 2007</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_512fadab-8270-4148-9bde-cd7dd5bd59bd"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Bausch &amp; Lomb Incorporated</span></p>
<p>Tampa, FL 33637</p>
<p>©Bausch &amp; Lomb Incorporated</p>
<p>9114600 <span class="Bold">(Folded)</span></p>
<p>9114700 <span class="Bold">(Flat)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Distributed by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_37046fb0-be50-44d6-a19b-25fed2098970"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0504a84a-0ba4-483b-9682-9bf3818410ee&amp;name=4697.jpg"></div>
<p class="First">NDC 54868-4697-1 </p>
<p></p>
<p>Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% (Sterile) </p>
<p>Rx only </p>
<p>[icon- eye] [icon- 1%] [icon- solution] [icon- 15 mL]</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOPENTOLATE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">cyclopentolate hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4697(NDC:24208-735)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPENTOLATE HYDROCHLORIDE</strong> (CYCLOPENTOLATE) </td>
<td class="formItem">CYCLOPENTOLATE HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4697-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040075</td>
<td class="formItem">01/10/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-4697)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b7a5e37c-1554-4ba6-8950-19e2bfddba69</div>
<div>Set id: 0504a84a-0ba4-483b-9682-9bf3818410ee</div>
<div>Version: 2</div>
<div>Effective Time: 20130206</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
